Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Bionano Genomics (Nasdaq: BNGO) announced that its CEO Erik Holmlin, PhD, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 8th, 2025, from 3:00 p.m. to 3:30 p.m. ET.

Investors can access the presentation through a webcast, and a replay will be available on Bionano's investor relations website at ir.bionano.com for a minimum of 30 days following the conference.

News Market Reaction

+2.50%

14 alerts

+2.50% News Effect

+3.5% Peak in 9 min

+$500K Valuation Impact

$21M Market Cap

0.7x Rel. Volume

On the day this news was published, BNGO gained 2.50%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $500K to the company's valuation, bringing the market cap to $21M at that time.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27^th Annual Global Investment Conference on Monday, September 8^th, 2025.

Conference & Webcast Details

Date:	September 8, 2025
Time:	3:00 p.m. to 3:30 p.m. ET
Presenter:	Erik Holmlin, PhD, CEO of Bionano
Webcast:	Link to Register

A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 30 days.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

Contacts

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com

FAQ

When is Bionano Genomics (BNGO) presenting at the H.C. Wainwright Conference?

Bionano Genomics will present on September 8th, 2025, from 3:00 p.m. to 3:30 p.m. ET.

Who will represent Bionano Genomics (BNGO) at the H.C. Wainwright Conference?

Erik Holmlin, PhD, Bionano's president and chief executive officer, will represent the company at the conference.

How can investors access Bionano's (BNGO) H.C. Wainwright Conference presentation?

Investors can access the presentation via webcast, and a replay will be available on Bionano's website at ir.bionano.com for at least 30 days after the conference.

How long will the replay of Bionano's (BNGO) presentation be available?

The presentation replay will be available on Bionano's investor relations website for at least 30 days following the conference.